Nuvation Bio announced $18.5 million in net product revenue for IBTROZI (taletrectinib) in Q1 2026, with strong adoption among newly treated patients with advanced ROS1-positive NSCLC. The company also acquired global development and commercialization rights to safusidenib, an investigational drug for IDH1-mutant glioma, expanding its oncology portfolio. Updated clinical data showed IBTROZI's durable response and progression-free survival, supporting its growing role as a standard treatment. Nuvation Bio maintains a strong cash position of $533.7 million and plans further updates on its drug conjugate platform later in 2026.
On June 15, 2026, BlackRock, Inc. and its funds reduced their total holdings in Orion Corporation to below 5% of the company's shares and voting rights. This change was disclosed under the Finnish Securities Market Act, indicating a decrease from a p...
Autonomize, a healthcare AI platform, has strengthened its leadership by appointing three industry veterans to its Advisory Board and hiring Mike Longacre as Head of Transformation. These moves aim to help healthcare organizations move beyond AI pilo...
Fairfax Financial Holdings has finalized its acquisition of Kennedy-Wilson Holdings at $10.90 per share in cash, led by a consortium including Kennedy Wilson's CEO William McMorrow and affiliates of Fairfax. The Kennedy Wilson management team retains...
Aya Gold & Silver Inc., a Canadian precious metals mining company operating in Morocco, will be added to the VanEck Gold Miners ETF (GDX) effective June 19, 2026. This inclusion marks a significant milestone reflecting the company's growth in product...
Nephros, Inc. emphasizes its ultrafiltration technology's ability to capture microplastics and nanoplastics in water, following the U.S. EPA's April 2026 decision to list microplastics as a priority contaminant under the Safe Drinking Water Act. The ...
